Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Amphastar Pharmaceuticals, Inc. (AMPH) Market Cap & Valuation Ratios

Amphastar Pharmaceuticals, Inc. (AMPH) has a market cap of $1.1B, a trailing P/E of 14.9 and a price-to-sales ratio of 1.5, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

AMPHAmphastar Pharmaceuticals, Inc.Follow AMPH — free
Drug Manufacturers - Specialty & Generic · Healthcare
—
Price chart with a free account
Market cap
1.1B
P/E TTM
14.9
Dividend yield
—
52-week
—
Next earnings
9 Nov, in 16 days

Peers

drug manufacturers - specialty & generic · nearest by market cap · trailing 12 months
CompanyMkt cap, $BP/EEV/SalesEV/EBITDAFCF yieldRev. growthOp. marginROIC
AMPH1.114.91.98.114.3%+1%16%8%
BCRX2.0—2.1—19.1%+69%-33%—
XERS1.9—5.952.53.0%+36%11%28%
ANIP1.715.72.08.110.4%+31%15%13%
PAHC1.615.91.59.10.6%+17%13%14%
PCRX1.5104.12.114.912.4%+6%3%2%
ETON1.4—13.568.61.0%+81%15%42%
CRON1.216.92.436.94.0%+37%-1%-0.5%
HROW1.1—4.6—0.5%+21%-1.0%-2%
COLL0.7—2.14.4—+14%19%9%
IRWD0.64.51.32.1—+26%60%—
Median of these 1015.92.112.03.5%+29%12%11%

P/E 14.9 vs. a peer median of 15.9; EV/Sales 1.9 vs. 2.1. AMPH's own P/E sits at the 42nd percentile of its history.

Growth vs. price

each dot a company · hover or tap for values
51020501000%+10%+20%+30%+40%revenue growth, TTM →P/E (log)AMPHANIPPAHCPCRXCRONIRWD

BCRX and XERS and ETON and HROW and COLL have no P/E (earnings not positive) and are left out · hover or tap a dot for values.

Amphastar Pharmaceuticals, Inc. — questions

What is Amphastar Pharmaceuticals, Inc.'s market cap?
$1.1B.
What is Amphastar Pharmaceuticals, Inc.'s P/E ratio?
14.9 on trailing twelve-month earnings to 2026-06-30.
What is Amphastar Pharmaceuticals, Inc.'s price-to-sales ratio?
1.5.

Every figure on this page comes from Amphastar Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.